Article
An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients.
AIDS (London, England) - 7 Dec 2001
Fauvel J, Bonnet E, Ruidavets J B, Ferrières J, Toffoletti A, Massip P, Chap H, Perret B
Abstract excerpt
BACKGROUND: Long-term therapy with protease inhibitors (PI) is associated with hypertriglyceridaemia, low high-density lipoprotein (HDL) levels and accumulation of apolipoprotein (apo) E- and apo C-III-containing lipoproteins. OBJECTIVES: To evaluate the impact, on this dyslipaemic phenotype, of three polymorphisms of the apo C-III gene: two on an insulin response element and one in the 3'-region. Apo E genotypes...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.